Comprehensive analysis of Edelweiss Business Cycle Fund - Regular (IDCW) (44924) providing detailed insights into fund performance, portfolio holdings, risk metrics, expense ratios, and investment recommendations.
Edelweiss Asset Mgt Ltd
The Fund seeks to generate long-term capital appreciation by investing predominantly in equity and equity related securities with a focus on navigating business cycles through dynamic allocation between various sectors and stocks at different stages of business cycles in the economy. There is no assurance that the investment objective of the Scheme will be achieved.
A comprehensive at-a-glance view of key mutual fund health indicators
Weak Returns
High Risk
High Expenses
Equity Focused
New Team
Below Average
Showing 1Y NAV history
Performance across different time periods
Fund shows concerning indicators. Exercise caution before investing.
Consider waiting for better market conditions or explore alternatives.
Fund shows concerning indicators. Exercise caution before investing.
Consider waiting for better market conditions or explore alternatives.
Recent performance momentum
Outperformance vs benchmark
Market exposure level
Assets under management
Risk-adjusted returns
Fund manager experience
Historical performance consistency
Fund management costs
This fund has underperformed its benchmark by 4.81% over the 3Y period.
See how your money can grow and compare with popular investment options
Disclaimer: Returns are illustrative and based on assumed rates. Mutual fund investments are subject to market risk. Please read scheme documents carefully.
| Company | Industry | % Assets |
|---|---|---|
| Net CA & Others | Debt Others | 5.34% |
| Divis Laboratories Ltd | Pharmaceuticals | 4.40% |
| Divis Laboratories Ltd | Pharmaceuticals | 4.38% |
| Max Healthcare Institute Ltd | Healthcare | 4.05% |
| Max Healthcare Institute Ltd | Healthcare | 4.00% |
| Fortis Healthcare Ltd | Healthcare | 3.92% |
| Coromandel International Ltd | Fertilizers | 3.75% |
| Coromandel International Ltd | Fertilizers | 3.37% |
| Fortis Healthcare Ltd | Healthcare | 3.28% |
| Max Financial Services Ltd | Finance | 3.23% |
Compare against Sectoral / Thematic category average
This comparison shows how the fund performs relative to the Sectoral / Thematic category average. Positive values indicate outperformance, while negative values show underperformance.
Compare with similar funds in Sectoral / Thematic category
| Fund Name | NAV | 1M | 3M | 6M |
|---|---|---|---|---|
| Aditya Birla SL MNC Fund - Direct (G) | ₹1524.25 | 3.51% | 14.28% | 3.38% |
| Aditya Birla SL MNC Fund - (G) | ₹1370.22 | 3.45% | 14.08% | 3.04% |
| Nippon India Banking&Financial Services-Dir(Bonus) | ₹702.57 | 4.13% | 14.57% | 15.30% |
| Nippon India Banking&Financial Services-Dir(G) | ₹702.57 | 4.13% | 14.57% | 15.30% |
| Nippon India Banking&Financial Services (Bonus) | ₹643.19 | 4.05% | 14.33% | 14.82% |
| Nippon India Banking&Financial Services (G) | ₹643.19 | 4.05% | 14.33% | 14.82% |
| Nippon India Pharma Fund - Direct (Bonus) | ₹575.71 | 2.71% | 9.40% | -1.82% |
| Nippon India Pharma Fund - Direct (G) | ₹575.71 | 2.71% | 9.40% | -1.82% |
| Franklin India Technology Fund - Direct (G) | ₹575.22 | 4.81% | 11.95% | -4.25% |
| ICICI Pru FMCG Fund - Direct (G) | ₹523.66 | 0.36% | 5.43% | 1.39% |
A seasoned investment professional with over 1 years of experience in equity research and fund management. Known for consistent performance and a disciplined investment approach focused on quality growth stocks.